---
title: "Primeton released its first-quarter performance, with a net loss attributable to the parent company of 27.5408 million yuan, narrowing the loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236954663.md"
description: "According to the Zhitong Finance APP, Primeton released its first-quarter report for 2025. The company's operating revenue for the first quarter of 2025 was RMB 37.2442 million, a year-on-year decrease of 38.58%; the net loss attributable to shareholders of the listed company was RMB 27.5408 million, with losses narrowing; the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was RMB 30.0937 million, with losses narrowing; the basic loss per share was RMB 0.300"
datetime: "2025-04-22T11:20:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236954663.md)
  - [en](https://longbridge.com/en/news/236954663.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236954663.md)
generator: "portal-rs"
---

# Primeton released its first-quarter performance, with a net loss attributable to the parent company of 27.5408 million yuan, narrowing the loss

According to the Zhitong Finance APP, Primeton (688118.SH) released its first-quarter report for 2025, showing an operating income of 37.2442 million yuan, a year-on-year decrease of 38.58%; a net loss attributable to shareholders of the listed company of 27.5408 million yuan, with losses narrowing; a net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses of 30.0937 million yuan, with losses narrowing; basic loss per share of 0.300 yuan/share

### Related Stocks

- [688118.CN](https://longbridge.com/en/quote/688118.CN.md)

## Related News & Research

- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [REG - China Yangtze Power - Semi-Annual Report of 2026](https://longbridge.com/en/news/297619698.md)
- [06:50 ETUnited Imaging secures CE mark for world's first dual wide-coverage CT family](https://longbridge.com/en/news/297901060.md)
- [10:17 ETDarkforce™ advances toward FedRAMP High for government deployment](https://longbridge.com/en/news/297666526.md)
- [Egetis says new Emcitate clinical data from Triac Trial II, ReTRIACt to be presented at September congresses](https://longbridge.com/en/news/297996002.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**